|
|
???tair.name??? >
???browser.page.title.author???
|
"belanger b"???jsp.browse.items-by-author.description???
Showing items 1-10 of 35 (4 Page(s) Totally)
1 2 3 4 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2020-10-10 |
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1
|
Chen, LT;Macarulla, T;Blanc, JF;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, JT |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2019-07-28 |
Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer
|
Chen, LT;Macarulla, T;Blanc, JF;Mirakhur, B;Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, JT |
| 國家衛生研究院 |
2019-02 |
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
|
Wang-Gillam, A;Hubner, RA;Siveke, JT;Von Hoff, DD;Belanger, B;de Jong, FA;Mirakhur, B;Chen, LT |
| 國家衛生研究院 |
2019-01 |
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Hubner, RA;Cubillo, A;Blanc, JF;Melisi, D;Von Hoff, DD;Wang-Gillam, A;Chen, LT;Becker, C;Mamlouk, K;Belanger, B;Yang, Y;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-10 |
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
|
Chen, LT;Macarulla, TM;Belanger, B;Mirakhur, B;de Jong, FA;Siveke, J |
| 國家衛生研究院 |
2018-10 |
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
|
Chen, LT;Macarulla, TM;Blanc, J;Mirakhur, B;de Jong, FA;Belanger, B;Bekaii-Saab, T;Siveke, J |
| 國家衛生研究院 |
2018-05 |
A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
|
Wang-Gillam, A;Hubner, R;Mirakhur, B;de Jong, F;Belanger, B;Chen, LT |
Showing items 1-10 of 35 (4 Page(s) Totally)
1 2 3 4 > >>
View [10|25|50] records per page
|
